Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial.
Saved in:
| Title: | Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial. |
|---|---|
| Authors: | Thiem VD; National Institute of Hygiene and Epidemiology, 1 Yersin Street, Hai Ba Trung District, Hanoi, Viet Nam., Anh DD; National Institute of Hygiene and Epidemiology, 1 Yersin Street, Hai Ba Trung District, Hanoi, Viet Nam., Ha VH; National Institute of Hygiene and Epidemiology, 1 Yersin Street, Hai Ba Trung District, Hanoi, Viet Nam., Van Thom N; Center for Disease Control, Thai Binh Province, 10 Hoàng Công Chất street, Quang Trung ward, Thai Binh, Viet Nam., Thang TC; PATH Vietnam, Hanoi Towers, 49 Hai Ba Trung Street, Hoan Kiem District, Hanoi, Viet Nam., Mateus J; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA., Carreño JM; Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP) at Mount Sinai New York, New York, NY, USA., Raghunandan R; Center for Vaccine Innovation and Access, PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA. Electronic address: rraghunandan@path.org., Huong NM; PATH Vietnam, Hanoi Towers, 49 Hai Ba Trung Street, Hoan Kiem District, Hanoi, Viet Nam., Mercer LD; Center for Vaccine Innovation and Access, PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA., Flores J; Center for Vaccine Innovation and Access, PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA., Escarrega EA; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA., Raskin A; Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP) at Mount Sinai New York, New York, NY, USA., Thai DH; Institute of Vaccines and Medical Biologicals, 9 Pasteur, Xuong Huan, Nha Trang City, Khanh Hoa, Viet Nam., Van Be L; Institute of Vaccines and Medical Biologicals, 9 Pasteur, Xuong Huan, Nha Trang City, Khanh Hoa, Viet Nam., Sette A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA; Department of Medicine, University of California, San Diego, (UCSD), La Jolla, CA, 92037, USA., Innis BL; Center for Vaccine Innovation and Access, PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA., Krammer F; Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP) at Mount Sinai New York, New York, NY, USA; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, NY, New York, USA. Electronic address: florian.krammer@mssm.edu., Weiskopf D; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA; Department of Medicine, University of California, San Diego, (UCSD), La Jolla, CA, 92037, USA. Electronic address: daniela@lji.org. |
| Source: | Vaccine [Vaccine] 2025 Jan 12; Vol. 44, pp. 126542. Date of Electronic Publication: 2024 Nov 29. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39615342 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Thiem+VD%22">Thiem VD</searchLink>; National Institute of Hygiene and Epidemiology, 1 Yersin Street, Hai Ba Trung District, Hanoi, Viet Nam.<br /><searchLink fieldCode="AU" term="%22Anh+DD%22">Anh DD</searchLink>; National Institute of Hygiene and Epidemiology, 1 Yersin Street, Hai Ba Trung District, Hanoi, Viet Nam.<br /><searchLink fieldCode="AU" term="%22Ha+VH%22">Ha VH</searchLink>; National Institute of Hygiene and Epidemiology, 1 Yersin Street, Hai Ba Trung District, Hanoi, Viet Nam.<br /><searchLink fieldCode="AU" term="%22Van+Thom+N%22">Van Thom N</searchLink>; Center for Disease Control, Thai Binh Province, 10 Hoàng Công Chất street, Quang Trung ward, Thai Binh, Viet Nam.<br /><searchLink fieldCode="AU" term="%22Thang+TC%22">Thang TC</searchLink>; PATH Vietnam, Hanoi Towers, 49 Hai Ba Trung Street, Hoan Kiem District, Hanoi, Viet Nam.<br /><searchLink fieldCode="AU" term="%22Mateus+J%22">Mateus J</searchLink>; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA.<br /><searchLink fieldCode="AU" term="%22Carreño+JM%22">Carreño JM</searchLink>; Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP) at Mount Sinai New York, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Raghunandan+R%22">Raghunandan R</searchLink>; Center for Vaccine Innovation and Access, PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA. Electronic address: rraghunandan@path.org.<br /><searchLink fieldCode="AU" term="%22Huong+NM%22">Huong NM</searchLink>; PATH Vietnam, Hanoi Towers, 49 Hai Ba Trung Street, Hoan Kiem District, Hanoi, Viet Nam.<br /><searchLink fieldCode="AU" term="%22Mercer+LD%22">Mercer LD</searchLink>; Center for Vaccine Innovation and Access, PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA.<br /><searchLink fieldCode="AU" term="%22Flores+J%22">Flores J</searchLink>; Center for Vaccine Innovation and Access, PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA.<br /><searchLink fieldCode="AU" term="%22Escarrega+EA%22">Escarrega EA</searchLink>; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA.<br /><searchLink fieldCode="AU" term="%22Raskin+A%22">Raskin A</searchLink>; Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP) at Mount Sinai New York, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Thai+DH%22">Thai DH</searchLink>; Institute of Vaccines and Medical Biologicals, 9 Pasteur, Xuong Huan, Nha Trang City, Khanh Hoa, Viet Nam.<br /><searchLink fieldCode="AU" term="%22Van+Be+L%22">Van Be L</searchLink>; Institute of Vaccines and Medical Biologicals, 9 Pasteur, Xuong Huan, Nha Trang City, Khanh Hoa, Viet Nam.<br /><searchLink fieldCode="AU" term="%22Sette+A%22">Sette A</searchLink>; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA; Department of Medicine, University of California, San Diego, (UCSD), La Jolla, CA, 92037, USA.<br /><searchLink fieldCode="AU" term="%22Innis+BL%22">Innis BL</searchLink>; Center for Vaccine Innovation and Access, PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA.<br /><searchLink fieldCode="AU" term="%22Krammer+F%22">Krammer F</searchLink>; Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP) at Mount Sinai New York, New York, NY, USA; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, NY, New York, USA. Electronic address: florian.krammer@mssm.edu.<br /><searchLink fieldCode="AU" term="%22Weiskopf+D%22">Weiskopf D</searchLink>; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA; Department of Medicine, University of California, San Diego, (UCSD), La Jolla, CA, 92037, USA. Electronic address: daniela@lji.org. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228406899%22">Vaccine</searchLink> [Vaccine] 2025 Jan 12; Vol. 44, pp. 126542. <i>Date of Electronic Publication: </i>2024 Nov 29. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science%22">Elsevier Science </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8406899 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1873-2518 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220264410X%22">0264410X </searchLink><i>NLM ISO Abbreviation: </i>Vaccine <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39615342 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.vaccine.2024.126542 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 126542 Titles: – TitleFull: Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Thiem VD – PersonEntity: Name: NameFull: Anh DD – PersonEntity: Name: NameFull: Ha VH – PersonEntity: Name: NameFull: Van Thom N – PersonEntity: Name: NameFull: Thang TC – PersonEntity: Name: NameFull: Mateus J – PersonEntity: Name: NameFull: Carreño JM – PersonEntity: Name: NameFull: Raghunandan R – PersonEntity: Name: NameFull: Huong NM – PersonEntity: Name: NameFull: Mercer LD – PersonEntity: Name: NameFull: Flores J – PersonEntity: Name: NameFull: Escarrega EA – PersonEntity: Name: NameFull: Raskin A – PersonEntity: Name: NameFull: Thai DH – PersonEntity: Name: NameFull: Van Be L – PersonEntity: Name: NameFull: Sette A – PersonEntity: Name: NameFull: Innis BL – PersonEntity: Name: NameFull: Krammer F – PersonEntity: Name: NameFull: Weiskopf D IsPartOfRelationships: – BibEntity: Dates: – D: 12 M: 01 Text: 2025 Jan 12 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1873-2518 Numbering: – Type: volume Value: 44 Titles: – TitleFull: Vaccine Type: main |
| ResultId | 1 |
